tbuckley/cabot-search huggingface dataset:
AB0069 Follistatin-like 1 Promotes Osteoclast Differentiation via RANKL-Mediated Activation of NF-κB and MAPK Signaling Pathways
Authors: H.-J. Kim, H.-J. Yoon, W.Y. Kang, S.J. Seong, Y.-R. Yoon
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Follistatin-like 1 (FSTL1) functions as a pivotal modulator of inflammation and is implicated in many inflammatory diseases such as rheumatoid arthritis, yet its role in osteoclast development is currently unknown. <h3>Objectives</h3> The aim of this study was to investigate the role of FSTL1 in osteoclast development mediated by M-CSF and RANKL. <h3>Methods</h3> Osteoclastogenesis was assessed using mouse primary bone marrow-derived macrophages. The mRNA expression was analyzed by real-time or RT-PCR. RANKL or M-CSF signaling was assessed by immunoblotting and NF-κB transcriptional activity by luciferase reporter assay. Apoptosis assay was performed by cell death ELISA and cell proliferation using BrdU ELISA system. <h3>Results</h3> We show that FSTL1 expression is strongly upregulated during osteoclast differentiation of bone marrow-derived macrophages (BMMs) and FSTL1 positively regulates receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis. The overexpression of FSTL1 or the treatment of recombinant FSTL1 (rFSTL1) in BMMs enhances the formation of multinuclear osteoclasts and the induction of c-Fos and nuclear factor of activated T cells c1 (NFATc1), transcription factors important for osteoclastogenesis. Conversely, knockdown of FSTL1 using a small hairpin RNA suppresses RANKL-mediated osteoclast formation and the expression of these transcription factors. While FSTL1 does not affect the RANKL-stimulated activation of p38 MAPK, the phosphorylation of IκBa, JNK, and ERK was increased by overexpression or addition of rFSTL1. Furthermore, rFSTL1 accelerated RANKL-induced NF-κB transcriptional activity in a dose-dependent manner. <h3>Conclusions</h3> Our study demonstrates that FSTL1 promotes osteoclast differentiation by stimulating NF-κB and MAPK activation in response to RANKL. Thus, we identify FSTL1 as a pro-osteoclastogenic factor that plays an important role in RANKL-induced osteoclast differentiation. <h3>References</h3> Teitelbaum, S. L. and F. P. Ross. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638–649. Chaly, Y. et al. 2012. FSTL1 promotes arthritis in mice by enhancing inflammatory cytokine/chemokine expression. Arthritis and rheumatism 64(4):1082–1088. Miyamae, T. et al. 2006. Follistatin-like protein-1 is a novel proinflammatory molecule. J Immunol 177(7):4758–4762. <h3>Acknowledgement</h3> This research was supported by the Basic Science Research Program of the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science, and Technology (NRF-2015R1D1A1A01056666) and the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health &amp; Welfare, Korea (HI15C0001, HI14C2750). <h3>Disclosure of Interest</h3> None declared
PTU-110 Long-Term Safety of Teduglutide Treatment for Patients with Intestinal Failure Associated with Short Bowel Syndrome: Pooled Data from 4 Clinical Trials
Authors: SM Gabe, U-F Pape, E Delmaestro, B Li, NN Youssef, D Seidner
Journal: Gut (2016)

<h3>Introduction</h3> Teduglutide (TED) is indicated for the treatment of adults with intestinal failure associated with short bowel syndrome (SBS-IF) who are dependent on parenteral support (PS). In phase III randomised placebo-controlled trials, TED significantly reduced PS volume requirements and number of PS infusion days per week in patients (pts) with SBS-IF. Here, we present combined safety data from TED-treated pts in these trials and their respective open-label extension studies. <h3>Methods</h3> Safety data were pooled from 4 TED clinical studies in adult pts with SBS–IF: two 24 week, double-blind, placebo-controlled trials with 2 respective open-label extensions of 28 weeks’ and 2 years’ duration (NCT-00081458, -00798967, -00172185, -0930644). <h3>Results</h3> Across 4 studies, 173 pts received subcutaneous TED (0.05 mg/kg/d, n = 134; 0.10 mg/kg/d, n = 39). 140 (81%) were treated with TED for ≥6 months and 111 (64%) were treated for ≥12 months; mean duration of TED exposure was 67 weeks. Most pts (97%) experienced ≥1 treatment-emergent adverse event (TEAE); the majority were mild (53%) or moderate (38%) in severity. TEAEs reported by ≥10% of pts were 42% abdominal pain; 29% upper respiratory tract infection; 27% catheter sepsis or nausea; 20% headaches or asthenic conditions; 19% injection-site reactions; 18.5% abdominal distension or urinary tract infections; 18% gastrointestinal (GI) stoma complications; 17% catheter site–related reactions or febrile disorders; and ≤15% vomiting, musculoskeletal pain, diarrhoea, fluid overload, hypersensitivity, or flatulence. The incidence rates of the most commonly reported GI adverse events (AEs) and fluid overload decreased over treatment time <b>(Table)</b>. TEAEs that led to premature discontinuation occurred in 20% of pts (n = 34); the most common was abdominal pain (5%; n = 8). Serious AEs (SAEs) were reported by 58% of pts (n = 101). The only SAE reported in ≥5% of TED-treated pts was catheter sepsis (25%; n = 43). As previously reported, 3 cases of malignant neoplasms occurred (metastatic adenocarcinoma, non–small-cell lung cancer, and squamous cell carcinoma). Metastatic adenocarcinoma was considered treatment related; this pt also had a history of Hodgkin disease treated with chemotherapy and radiation. <h3>Conclusion</h3> TED was generally well tolerated in pts with SBS-IF. No new safety signals were identified in the pooled analysis. The most frequently reported AEs were consistent with the underlying disease condition and known mechanism of action of TED and were reported early in the treatment period. Data from phase III trials demonstrate the safety of long-term TED treatment. <h3>Disclosure of Interest</h3> None Declared
Performance of screening questionnaires for obstructive sleep apnea during pregnancy: A systematic review and meta-analysis
Authors: Visasiri Tantrakul, Pawin Numthavaj, Christian Guilleminault, Mark McEvoy, Panyu Panburana, Win Khaing, John Attia, Ammarin Thakkinstian
Journal: Sleep Medicine Reviews (2016)

This review aims to evaluate the performance of obstructive sleep apnea (OSA) screening questionnaires during pregnancy. A systematic review and meta-analysis was performed using MEDLINE Scopus, CINAHL, and the Cochrane library. A bivariate meta-analysis was applied for pooling of diagnostic parameters. Six of the total 4719 articles met the inclusion criteria. The Berlin questionnaire (BQ, N = 604) and Epworth sleepiness scale (ESS, N = 420) were the most frequently used screening tools during pregnancy. The pooled prevalence of OSA during pregnancy was 26.7% (95%CI: 16.9%, 34.4%, I2 = 83.15%). BQ performance was poor to fair with pooled sensitivity and specificity of 0.66 (95%CI: 0.45, 0.83; I2 = 78.65%) and 0.62 (95%CI: 0.48, 0.75; I2 = 81.55%), respectively. BQ performance was heterogeneous depending on type of reference test and pregnancy. Sensitivity increased if diagnosis was based on polysomnography (0.90), and respiratory disturbance index (0.90). However, sensitivity decreased if screening was performed in early pregnancy (≤20 weeks gestation: 0.47), and high-risk pregnancy (0.44). Performance of ESS was poor with pooled sensitivity and specificity of 0.44 (95%CI: 0.33, 0.56; I2 = 32.8%) and 0.62 (95%CI: 0.48, 0.75; I2 = 81.55%), respectively. In conclusion, BQ and ESS showed poor performance during pregnancy, hence a new OSA screening questionnaire is needed. Registration: PROSPERO registration CRD42015025848.
Exclusion of SERUM Thymidine Kinase Does NOT Reduce the Predictive VALUE of a Comprehensive Prognostic INDEX in Chonic Lymphocytic Leukemia. Results of an External Validation on a Prospective Cohort of Patients with EARLY Disease
Authors: Stefano Molica, Diana Giannarelli, Luciano Levato, Mirabelli Rosanna, Massimo Gentile, Fortunato Morabito
Journal: Blood (2014)
Painful Papulonodule on the Foot of a Patient With Human Immunodeficiency Virus
Authors: Van Phan, Lulit Price, Karolyn A. Wanat
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
The Importance of Harmonizing Transplantation Procedures in Children with ALL: ALL-SCT-BFM 2003, a Prospective Multicenter Trial.
Authors: André Schrauder, Arend Stackelberg, Martin Schrappe, Thomas Klingebiel, Wolfgang Holter, Karl-Walter Sykora, Rupert Handgretinger, Wolfram Ebell, Ulrike Pötschger, Martin Zimmermann, Susanne Karlhuber, Christina Peters
Journal: Blood (2007)
BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire.
Authors: Cihangir Duy, J. Jessica Yu, Srividya Swaminathan, Rahul R. Nahar, Soo-mi Kweon, Jose M. Polo, Ester Valls, Lars Klemm, Leandro Cerchietti, Gregor von Levetzow, Sebastian Herzog, Hassan Jumaa, Ignacio Moreno de Alborán, Ari Melnick, B. Hilda Ye, Markus Müschen
Journal: Blood (2009)
Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79
Authors: Jeroen Lammerts van Bueren, Danielle Jakobs, Niels Kaldenhoven, Marcel Roza, Sanne Hiddingh, Joyce Meesters, Marleen Voorhorst, Elke Gresnigt, Luus Wiegman, Antonio Ortiz Buijsse, Grietje Andringa, Marije B. Overdijk, Parul Doshi, Kate Sasser, Michel de Weers, Paul W.H.I. Parren
Journal: Blood (2014)
Rituximab Sensitizes TRAIL-Resistant B-NHL Lines to Apoptosis by Both TRAIL and Fully Humanized Antibodies Targeting TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumumab).
Authors: Mario I. Vega, Sara Huerta-Yepez, Stavroula Baritaki, Melisa A. Martinez-Paniagua, Cesar R. Gonzalez-Bonilla, Benjamin Bonavida
Journal: Blood (2007)
Multiple Myeloma Cells Survival and Proliferation Rely on High Levels and Activity of the Serine-Threonine Kinase CK2.
Authors: Francesco A. Piazza, Maria Ruzzene, Giovanni Di Maira, Enrico Brunetta, Luca Bonanni, Livio Trentin, Renato Zambello, Lorenzo A. Pinna, Gianpietro Semenzato
Journal: Blood (2004)
Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present
Authors: V F A M Derksen, S Ajeganova, L A Trouw, A H M van der Helm-van Mil, I Hafström, T W J Huizinga, R E M Toes, B Svensson, D van der Woude
Journal: Annals of the Rheumatic Diseases (2016)

Objectives In rheumatoid arthritis (RA), seropositive and seronegative disease may be two entities with different underlying pathophysiological mechanisms, long-term outcomes and disease presentations. However, the effect of the conjoint presence of multiple autoantibodies, as proxy for a more pronounced humoral autoimmune response, on clinical phenotype remains unclear. Therefore, this study investigates the association between the number of autoantibodies and initial clinical presentation in two independent cohorts of patients with early RA. Methods Autoantibody status (rheumatoid factor, anticitrullinated protein antibodies and anticarbamylated protein antibodies) was determined at baseline in the Leiden Early Arthritis Cohort (n=828) and the Swedish BARFOT (Better Anti-Rheumatic Farmaco-Therapy, n=802) study. The association between the number of autoantibodies and baseline clinical characteristics was investigated using univariable and multivariable ordinal regression. Results In both cohorts, the following independent associations were found in multivariable analysis: patients with a higher number of RA-associated antibodies were younger, more often smokers, had a longer symptom duration and a higher erythrocyte sedimentation rate at presentation compared with patients with few autoantibodies. Conclusions The number of autoantibodies, reflecting the breadth of the humoral autoimmune response, is associated with the clinical presentation of RA. Predisease pathophysiology is thus reflected by the initial clinical phenotype.
Validating Metal‐Organic Framework Nanoparticles for Their Nanosafety in Diverse Biomedical Applications
Authors: Stefan Wuttke, Andreas Zimpel, Thomas Bein, Simone Braig, Katharina Stoiber, Angelika Vollmar, Dominik Müller, Kirsten Haastert‐Talini, Jörn Schaeske, Meike Stiesch, Gesa Zahn, Alexander Mohmeyer, Peter Behrens, Oliver Eickelberg, Deniz A. Bölükbas, Silke Meiners
Journal: Advanced Healthcare Materials (2016)

Metal-organic frameworks (MOFs) are promising platforms for the synthesis of nanoparticles for diverse medical applications. Their fundamental design principles allow for significant control of the framework architecture and pore chemistry, enabling directed functionalization for nanomedical applications. However, before applying novel nanomaterials to patients, it is imperative to understand their potential health risks. In this study, the nanosafety of different MOF nanoparticles is analyzed comprehensively for diverse medical applications. The authors first evaluate the effects of MOFs on human endothelial and mouse lung cells, which constitute a first line of defense upon systemic blood-mediated and local lung-specific applications of nanoparticles. Second, we validated these MOFs for multifunctional surface coatings of dental implants using human gingiva fibroblasts. Moreover, biocompatibility of MOFs is assessed for surface coating of nerve guidance tubes using human Schwann cells and rat dorsal root ganglion cultures. The main finding of this study is that the nanosafety and principal suitability of our MOF nanoparticles as novel agents for drug delivery and implant coatings strongly varies with the effector cell type. We conclude that it is therefore necessary to carefully evaluate the nanosafety of MOF nanomaterials with respect to their particular medical application and their interacting primary cell types, respectively.
Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS
Authors: Arati Rao, Ghazi Khan, David A. Rizzieri, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Anne W Beaven, Donna Adams, Julie Warzecho, Carlos Decastro
Journal: Blood (2012)
The Well-Known Gene <i>HHIP</i> and Novel Gene <i>MECR</i> Are Implicated in Small Airway Obstruction
Authors: Diana A. van der Plaat, Kim de Jong, Lies Lahousse, Alen Faiz, Judith M. Vonk, Cleo C. van Diemen, Ivana Nedeljkovic, Najaf Amin, Ma’en Obeidat, Cornelia M. van Duijn, H. Marike Boezen, Dirkje S. Postma
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
Impact of Post-Remission Consolidation Modalities in the Clinical Outcomes of Acute Myeloid Leukemia Patients in First Remission - Is There a Role for Autologous Hematopoietic Stem Cell Transplant?
Authors: May Anne Cheong, Gee Chuan Wong, William YK Hwang, Ho YL Aloysius, Yeh Ching Linn, Yeow-Tee YT Goh, Yvonne Loh, Sathish Kumar, Colin Phipps, Zhentang Lao
Journal: Blood (2015)
Acute Myeloid Leukemia and Survival on the Intensive Care Unit (ICU) - Biology- and Treatment-Related Determinants of Outcome - An Analysis of the AML-CG
Authors: Bernhard Heilmeier, Johannes Thudium, Matthias Kochanek, Christoph Schmid, Joachim Stemmler, Karl-Anton Kreuzer, Michael Hallek, G\)nter Schlimok, Karsten Spiekermann, Wolfgang Hiddemann, Jan Braess
Journal: Blood (2010)
AB0758 The Relationships between Bone Mineral Density and Radiographic Features of Hand or Knee Osteoarthritis in Older Adults: Data from The Dong-Gu Study
Authors: K.-E. Lee, L. Wen, Y.-R. Yim, J.-E. Kim, J.-W. Lee, D.-J. Park, S.-S. Lee
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> The relationship between osteoarthritis (OA) and osteoporosis has exhibited contradictory features over the past four decades. The aim of this study was to evaluate this relationship using separate analysis of the radiographic features of OA whether various radiographic features of OA were associated differently with bone mineral density (BMD) in the Korean elderly. <h3>Methods</h3> Data were derived from the Dong-gu cohort; 2,354 subjects were enrolled in the present cross-sectional study. Baseline characteristics, the BMDs of the lumbar spine and femoral neck which was measured by DXA, and X-rays of knees and hands, were collected. A semi-quantitative grading system was used to estimate the severities of individual radiographic features. We adjusted for confounders using multiple linear regression modeling to analyze the relationships. <h3>Results</h3> After adjustment for confounders, hand and knee OA total scores were negatively associated with the BMDs of the lumbar spine and femoral neck, except for the total knee OA score and lumbar spine BMD. In detail, hand osteophytes and sclerosis exhibited positive relationships with the BMDs of the lumbar spine and femoral neck, except for hand osteophytes and femoral neck BMD. On the contrary, however, knee joint space narrowing (JSN), hand JSN, and hand subchondral cysts were negatively associated with the BMD of the lumbar spine and femoral neck. Knee JSN and hand subchondral cysts exerted the greatest effects on BMD. <h3>Conclusions</h3> Separate analysis of the radiographic features of OA better reveals associations of OA with the BMD of the lumbar spine and femoral neck. <h3>Disclosure of Interest</h3> None declared
ATPS-95THE PROGNOSTIC AND PREDICTIVE VALUE OF AN EXPLANT ASSAY OF GLIOMAS IN RESPONSE TO TEMOZOLOMIDE
Authors: Amparo Wolf, Warren McDonald, David MacDonald, Joseph Megyesi, Penny Costello
Journal: Neuro-Oncology (2015)

INTRODUCTION: Glioblastoma Multiforme (GBM) is the most common and lethal primary adult brain tumor, with significant variability in therapeutic response due to its underlying molecular and pathological heterogeneity. This study investigated the prognostic and predictive value of an established explant assay of surgical specimens of gliomas in response to the clinically relevant chemotherapy temozolomide (TMZ). METHODS: One hundred and thirty-eight patients with pathologically-verified gliomas and ongoing follow-up of clinical outcomes were included in the study. Tumor specimens at the time of resection were plated onto a collagen matrix with and without TMZ. Using video microscopy, the migratory distance of the cells was quantified over 5 days. RESULTS: One hundred and eleven viable explant assays were collected in glioma patients including 65 GBMs, 19 anaplastic, 13 grade II and 14 recurrent high grade glioma. GBMs showed increased invasiveness compared to anaplastic and grade II gliomas on the assay. Glioma patients whose tumors showed a greater invasive distance on the assay had reduced overall survival. Inhibition of invasion by 20% by TMZ on the explant assay predicted the time to recurrence after TMZ treatment and the overall survival of GBM patients. CONCLUSION: This study demonstrates that an explant assay of surgical specimens of gliomas, by reproducing the in vivo environment, can predict overall survival of gliomas patients and response to temozolomide. Investigations are ongoing to determine whether response on the assay is of predictive value beyond genetic markers including MGMT and IDH1.
Screening for amblyopia in preverbal children with photoscreening photographs 11The authors have no proprietary interest in the instrument described in this paper nor in any other vision screening device.
Authors: Patrick Y Tong, Jennifer P Macke, Roger E Bassin, Mary Everett, Erinn Enke-Miyazaki, James M Tielsch, David R Stager, Marshall M Parks, George R Beauchamp
Journal: Ophthalmology (2000)
Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.
Authors: James A. Russell, Nizar J. Bahlis, Mary Lynn Savoie, M. Ahsan Chaudhry, A. Robert Turner, Loree M. Larratt, Diana M. Quinlan, Christopher Brown, Alexander Balogh, Jan Storek, Michelle Geddes, Douglas A. Stewart
Journal: Blood (2006)
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia
Authors: A-K Eisfeld, J Kohlschmidt, S Schwind, D Nicolet, J S Blachly, S Orwick, C Shah, M Bainazar, K W Kroll, C J Walker, A J Carroll, B L Powell, R M Stone, J E Kolitz, M R Baer, A de la Chapelle, K Mrózek, J C Byrd, C D Bloomfield
Journal: Leukemia (2016)
A Novel Humanized Bone Marrow Niche Xenotransplantation Model Allows Superior Engraftment of Human Normal and Malignant Hematopoietic Cells and Reveals Myelofibrosis-Initiating Cells in the HSC Compartment
Authors: Andreas Reinisch, Dita Gratzinger, Wan-Jen Hong, Ravi Majeti
Journal: Blood (2014)
A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191
Authors: Annette E Hay, Alli Murugesan, Ashley M. DiPasquale, Tom Kouroukis, Irwindeep Sandhu, Vishal Kukreti, Nizar J Bahlis, Johan Lategan, Donna E. Reece, John F. Lyons, Joana Sederias, Jean Powers, Hao Xu, Lesley K. Seymour, Anthony Reiman
Journal: Blood (2014)
Alemtuzumab (CAMPATH®, MABCAMPATH®) Has Superior Progression Free Survival (PFS) vs Chlorambucil as Front-Line Therapy for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (BCLL).
Authors: Peter Hillmen, Aleksander Skotnicki, Tadeusz Robak, Branimir Jaksic, Cynthia Sirard, Jiri Mayer
Journal: Blood (2006)
Risk Factors for Acute and Chronic Gvhd after Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Relative Risks with Umbilical Cord Blood (UCB) and Matched Related Donors (MRD)
Authors: Aleksandr Lazaryan, Todd E. DeFor, Claudio Brunstein, Margaret L. MacMillan, Nelli Bejanyan, Shernan G. Holtan, Bruce R. Blazar, John E Wagner, Daniel J. Weisdorf, Mukta Arora
Journal: Blood (2014)
Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia
Authors: Eda Tanrikulu Simsek, Ahmet Emre Eskazan, Mahir Cengiz, M. Cem Ar, Seda Ekizoglu, Ayse Salihoglu, Emine Gulturk, Tugrul Elverdi, Seniz Ongoren Aydin, Ahu Senem Demiroz, Ayse Nur Buyru, Zafer Baslar, Ugur Ozbek, A. Burhan Ferhanoglu, Yildiz Aydin, Nukhet Tuzuner, Teoman Soysal
Journal: Blood (2015)
The Acetylation of AML1-ETO Is Required for Leukemogenesis.
Authors: Lan Wang, Alexander Gural, Fabiana Perna, Xiaojian Sun, Xinyang Zhao, Haiming Xu, Megan A Hatlen, Gang Huang, Fan Liu, Hao Xu, Tony Deblasio, Silvia Menendez, Francesca Voza, Robert Roeder, Stephen Nimer
Journal: Blood (2010)